Publications by authors named "Breno Moreno de Gusmao"
Article Synopsis
- * While promising, this therapy poses challenges, including cardiovascular toxicity, with recent studies suggesting a significant risk of side effects related to cytokine release syndrome, which can lead to serious heart complications.
- * The review discusses the connection between cytokine release syndrome and heart issues from the therapy, examining risk factors for cardiotoxicity and offering guidelines for patient assessments before and after treatment.
The use of non-cryopreserved hematopoietic stem cells (HSC) can be an alternative to the traditional cryopreserved infusions of HSCs in autologous stem cell transplantation (aHSCT). After high-dose melphalan conditioning (HDM), we sought to compare time to engraftment, overall survival, and safety in multiple myeloma (MM) patients undergoing a first aHSCT after high-dose melphalan conditioning (HDM). We conducted a cohort study from March 2018 to December 2019.
View Article and Find Full Text PDFCardiac amyloidosis is associated with a high mortality rate, a long delay between the first signs and the diagnosis but a short interval between diagnosis and death. This scenario has changed recently due to improved disease awareness among doctors and significant progress in diagnosis thanks to multimodal imaging and a multidisciplinary approach. Therefore, during the last few years, we have had access to specific therapies for those patients.
View Article and Find Full Text PDFImpact of Treatment Prior to Allogeneic Transplantation of Hematopoietic Stem Cells in Patients with Myelodysplastic Syndrome: Results of the Latin American Bone Marrow Transplant Registry.
Biol Blood Marrow Transplant
May 2020
It has been suggested that bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) can be valuable in the treatment of patients with myelodysplastic syndromes (MDS). However, the influence of this approach on HSCT outcomes remains poorly defined. Therefore, our objective was to investigate the influence of treatment before HSCT in patients with MDS.
View Article and Find Full Text PDFAims And Objectives: To estimate the prevalence of difficult venous access in complex patients with multimorbidity and to identify associated risk factors.
Background: In highly complex patients, factors like ageing, the need for frequent use of irritant medication and multiple venous catheterisations to complete treatment could contribute to exhaustion of venous access.
Design: A cross-sectional study was conducted.
Context And Objective: For the last nine years, hematologists and oncologists have gathered annually at an educational symposium organized by a Brazilian and an American hospital. During the 2015 Board Review, a survey among the attendees evaluated the differences in management and treatment methods for multiple myeloma (MM).
Design And Setting: Cross-sectional study during an educational hematology symposium in São Paulo, Brazil.